Abbott initiates ABT-806 Phase 1 trial in EGFR expressing tumors

Life Science Pharmaceuticals (LSP) announced today a milestone related to monoclonal-antibody (mAb) 806 licensed to Abbott. A Phase 1 trial with ABT-806, a humanized version of mAb 806 that selectively targets the epidermal growth factor receptor (EGFR), has been initiated by Abbott in the U.S. The trial will assess the safety and pharmacokinetics of ABT-806 in patients with advanced solid tumors likely or known to express EGFR. A clinical study of the chimeric predecessor mAb, ch806, published in PNAS, suggested an ability to target and bind to EGFR expressing tumors selectively, with essentially no targeting of normal tissues. Preclinical data show that ABT-806 may be effective in treating multiple tumor types.

"We are hopeful that ABT-806 will confirm the preclinical studies performed by Abbott and the Ludwig Institute in humans. We look forward to further expanding our knowledge of mAb 806 with this trial," noted James Fiore, CEO of LSP.